Elite Pharmaceuticals Inc (QB) (ELTP) 시세

Only for the 1st 100 shoppers.

Someone wanted cash for early Black Friday deals. 😀

Selling seems to have dried up.

December or January is just a matter of a few weeks. Big deal if it slips. Would rather they get it right than rush it. 

The short trap is set

With Thanksgiving next week and half day next Friday, there are only 4 more trading days this month. Nasrat has indicated that he would start working on a launch of Vyvanse immediately. If he announces the launch in December, the stock should react very nicely.

Got a few more people buying, setup weekly order myself among my other buys between various accounts. Under $0.65 is a nice intro price for noobs, tell your friends!

Form 4's aren't filed day of trading. Few business day window to file if that is the case. 

Doubt it. Massive shorting of elite buys them nothing. Elite isn't at a great need to hit the markets for cash flow. If we get a massive API allotment then that's a different story as we need to fund it upfront, but we can take on more short-term debt as Nasrat stated. We just need to get through this next year to grow Vyvanse market capture and then we'll be set for future big launches.

Since the sells and offers have remained low, I believe that the selling is from another insider shareholder who has given the market maker a sixty cent price he wants for his 1 million shares which have gone off in blocks. Doug, the prior big seller ,was satisfied with 50 cents since he was replacing the shares in January by exercising his warrants. Like Black Friday, a smart shopper uses deep discount sales to buy. Expect to see a Form 4 after the close. My suggestion is to Relax. Cue Frankie Goes to Hollywood.

Does anybody Think some entity associated with Purdue pharmaceuticals, or someone related to them are behind the shorting of ELT or down pressure on the stock price due to the lawsuit and coming out with a generic

Recent price action suggests that while people are learning about Elite, some are definitely the wrong kind of people, I.e. "bears" who would like nothing more than to short the price down to nothing. The Vyvanse news came early. Let us "longs" hope that something more comes soon to run the "bears" off. "Nothing runs like a bear."

WE have NASDAQ in the horizon too - but the Buyout WILL surprise all of us when it happens

For me, I take Synthroid....brand name. I found levoxyl to not work as well.....
just my 2 cents.

What the hell is going on here Wehad great results,billion dollar needle mover and we are dropping like a stone .I just don’t get it

We might have to wait until the Feb CC to get market to believe Elite's potential. But the big numbers will come in the CC after that way out in late Jun/early Jul 2025. But throwing a BE into the mix with the upcoming launches could change our near-term fortunes in a minute. Elite has a plan for building a portfolio for a buyout/merger and is executing it like clockwork.

People who wanted a big quick pay off are exiting. Good luck to them!

Generic Rx card? I have never heard of that and I live in the healthcare world. Rx plans will often prioritize generics over brand unless there is a pre-authorization granted when generics don't work. 

1/2 ownership of the profit split of Adderalls ($2B market) = $0.60

Full ownership of Vyvance ($4.3B) = $0.02 more

Todays price $$0.62

I think most people who have insurance today have a generic prescription card. Generic first then brand unless Doctor specifies brand on scrip

Well time to buy the dip. Let’s see how low this thing decides to go. Owning this dam stock is one hell of a dam ride

Traders and short term players can do what they want and sell as they please. I'm happy as a clam knowing where Elite is headed. Smooth sailing...

Elite has 3 additional product launches in the next few months. Hydrocodone with aPAP, which is the generic for Norco, which is expected to launch in the next few weeks, I would say around the 1st week of December.

Nasrat has not sold a single share of ELTP. Perhaps the income he gets from Mikah makes it unnecessary to take any ELTP profit off the table.

CC: We are in a position that is very attractive for a pharmaceutical company with consistent profits, steady growth and low debt, and we are in a great position, a strong position for merger and acquisition, if the price is right, or a move up to NASDAQ.

Does anyone know how much Nasrat makes through Mikah off of the sweet deal ? What’s his annual take in profit

Nasrat:
The building, of course, as I update you before, all the permits are approved. New Jersey Department of Health approved us. DEA approved us. And about a week ago, okay, they came in for another inspection as if we're functioning as a full blown facility. And we we told them that, we're waiting for the FDA.

We have made the registration batches, and we will be filing them sometime this month or early December. The, 3 months stability is up at the end of this month. So we'll file, early next month. And hopefully, 30 days later, if we don't hear from FDA, we will, go ahead and start utilizing the facility, I would say, in January, unless the FDA says, don't do it till we come and look at it. We intend to start utilizing it as of January.

Great - so Nasrat had mentioned that it was in shortage - and apparently Elite succeeded to put their hand on more API...

Why da fuq would people/insurance pay for the brand when a generic is available?

Never understood this.

Lol. That would be nice, but you are forgetting that brand name Vyvanse is available. I do agree that there is an incredible opportunity here for Elite.

Regarding Elite’s Adderall ER and IR, I’m seeing a lot of out of stocks on the various strengths at Cardinal. Most likely because Elite has sold their entire quota of these products. I know the FDA site say “Available” , but that is not my current experience. As HGilS mentioned, Elite’s team has dealt successfully with the DEA getting quota in the past. Hopefully they get additional quota soon.

Elite should take $4.2 billion of the $4.3 billion dollar Vyvanse market.

Hire several dozen more people and run Elite's facilities 24/7.

No, I am not joking.

Once in a lifetime opportunity here.

Elite has a wide open field for generic Vyvanse. As I mentioned recently, for most strengths every generic manufacturer has no product available to order from Cardinal. It’s probably the same at McKesson and AmeriSource Bergen, but I don’t know that for sure.

Yes

https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c

What about Naltrexone? Do you have any stats?

Loaded powder, but can't buy elite cause unsettled funds + penny stock. Such is life...

On the shortage page Elite passed with flying colors again, on the 19th,

https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1

The FDA just loves Nasrat, they keep coming around

As far as Mikah is concerned, WeeZuhl already has a lawyer lined up if Nasrat attempts to sell Elite without full ownership of the Adderalls.

Would be embarrassing for Nasrat to spend his retirement in the courtroom instead of on the beach.

ELTP Catalysts:

X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $4.7 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Final Approval of New Manufacturing Facility/Expansion
__28. Double output of manufacturing and packaging facilities
X 29. Launch approved generic Tylenol with Codeine $47 Million
__30. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__31. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
X 33. Godzilla -Generic Vyvanse Approval $4.3 Billion
__34. Positive BE Study for Concerta CNS Stimulant $1.2 Billion
__35. Godzilla - Generic Vyvance LAUNCH $4.3 Billion
__36. Generic Concerta- FDA submission $1.2 Billion
__37. $100 million in yearly revenues
__38. Generic OxyContin Tentative Approval $720 Million
__39. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__40. Launch generic OxyContin $720 Million
__41. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone - Game Over Drug
__42. Resume R&D on SequestOx Abuse Deterrent Oxycodone
X 43. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
X 44. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
__45. $200 million in yearly revenue
__46. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__47. Undisclosed Mikah ANDA(s)
__48. Undisclosed ANDAs/NDAs
__49. Generic Concerta Launch $1.2 Billion
__50. DollarLand PPS
__51. Big Pharma bidding
__52. UpList to the NASDAQ Exchange
__53. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__54. Vegas BABY !!!!!

WHY WHY WHY?
Why do I make the mistake to put you off from ignore every few weeks?

Hi Nas, I recommend that you split the Vyvanse approval and Launch as 2 lines with one checked.

Thanks

What Ive see. happen multiple times is that all options immediately vest upon a M&A transaction, including future options. The future date doesn't need to take arrive before Carter and others cash these in. An acquisition can make that happen sooner. 

CC's are not a requirement. I know one company where the CFO of a publicly held organization that filed the quarterly 10Q's, but only held one live CC per year, the annual. Rest of communication was through PRs. 

As we both know "nasrat said" is not even close to a guarantee !!!!!!!!!!!

I only go by what "nasrat did" .....

How many ANDA's has "nasrat said" would be filed in 2024 ???????????

How many were actually filed ???????????

Hey Thanks A Lot King,

IB_🤴

Upcoming ELTP Catalysts:

Next 1 day-6 months:


X 1. Cash Flow Positive - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million IMS market Approved and Launched
X 4. Adderall XR $1.56 Billion IMS market Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement - January 1st 2024
X 8. First shipment Adderall XR to Prasco/Burel Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
X 11. Generic Vyvanse - $4.7 BILLION - FDA submission Dec 2023
X 12. FDA Acceptance of Generic OxyContin Sept 2023
X 13. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__14. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
__15. Obtain Full ownership of Adderall IR $ 335 Million from MIKAH
__16. Obtain Full ownership of Adderall XR $ 1.56 Billion from MIKAH
X 17. Vigabatrin Approval $233 Million
X 18. Pyros Vigabatrin -settle VigPoder trade mark challenge and LAUNCH
X 19. Generic Methotrexate Antimetabolite- Approval
X 20. Launch generic Methotrexate $63.4 Million
X 21. $50+ million in yearly revenues
X 22. Lowest PE ratio for OTC Healthcare sector
X 23. Become the ONLY company showing rapid growth on the OTC while being profitable
X 24. Put Opioids back on the Table- due to reduced risk of opioid litigation
X 25. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
__26. Generate revenues over $20 million/quarter
__27. Positive BE Study for Concerta CNS stimulant
__28. Final Approval of New Manufacturing Facility/Expansion
__29. Double output of manufacturing and packaging facilities
X 30. Launch approved generic Tylenol with Codeine $47 Million
__31. Launch approved generic Norco - hydrocodone acetaminophen IMS $477 Million
__32. Launch approved generic Percocet - oxycodone acetaminophen IMS $500 Million
__33. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__34. Godzilla - Generic Vyvanse Approval and Launch $4.7 BILLION
__35. Generic Concerta- FDA submission $1.2 BILLION
__36. $100 million in yearly revenue
__37. Generic OxyContin Tentative Approval $720 Million
__38. Elite prevail over Purdue in Generic OxyContin infringement suit - second 6 month stay - active Accord/Purdue suit causing delay
__39. Launch generic OxyContin $720 Million
__40. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone - Drug C in SequestOx reformulation trial -Game Over Drug
__41. Resume R&D on SequestOx Abuse Deterrent Oxycodone
X 42. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
X 43. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
__44. $200 million in yearly revenue
__45. Undisclosed Mikah ANDA(s)
__46. Undisclosed ANDAs/NDAs
__47. Generic Concerta Approval and Launch

__48. DollarLand PPS
__49. Big Pharma bidding
__50. UpList to the NASDAQ Exchange
__51. ELTP Elite Pharmaceutical Buyout - 2 1/2 years or less from Feb 2024
__52. Vegas !!!!!
Bullish

The pps never went to $0.75 that was a mirage.

And here are Carter Ward's options:

3,000,000 shares.

- "Options vest in equal annual increments of 1,000,000 shares on September 5, 2024, September 5, 2025 and September 5, 2026.

Nasrat wants the buyout in early 2027 to be as clean as possible.

So he's letting the Prasco agreement expire without renewal in March 2025 and he's letting the Tagi agreement expire without renewal in August 2025.

What are thoughts on Prasco/Burel relationship ending? Thought this was interesting. Clearly going the way of driving their own exclusive line, noting once again when Tagi's contract is up for renewal next year as well.

I've LITERALLY said that AT LEAST a dozen times on this board.

Now Nasrat COPIES The King because he knows how good it sounds.

LOL! We are "MEGA" - Make Elite Great Again! Hahahahahahahaha

Nasrat has LITERALLY mentioned Nasdaq EVERY single year since 2014 on NEARLY every conference call.

It means absolutely nothing.

He mentioned NASDAQ again.

Great investment in R&D. Nasrat has said they will only develop the big drugs who have $1B+ annual sale. So we should see our pipeline get better and better.